Atopic Dermatitis: 5 Things to Know Atopic Dermatitis: 5 Things to Know
From subtle differences in presentation to diagnostic pearls and the newest and emerging treatments, check out these 5 things to know about atopic dermatitis.Medscape Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 11, 2023 Category: Allergy & Immunology Tags: Dermatology Commentary Source Type: news
Three Tuberculosis Vaccines Reach Final Stage of Development Three Tuberculosis Vaccines Reach Final Stage of Development
Around 15 vaccine candidates are being developed in the battle against tuberculosis to compensate for the poor efficacy of the Bacillus Calmette-Gu érin vaccine.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 11, 2023 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news
RVUs: A Fair Measure of Your Productivity? RVUs: A Fair Measure of Your Productivity?
Curious about how physicians ' productivity and compensation are measured through RVUs? Dr Alok S. Patel breaks down the intricacies of this complex system and explores its impact on the medical field.Medscape Hospital Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 11, 2023 Category: Allergy & Immunology Tags: Hospital Medicine Commentary Source Type: news
S2 Episode 5: The Future of Asthma Care: Glass Half Empty or Half Full? S2 Episode 5: The Future of Asthma Care: Glass Half Empty or Half Full?
Join Drs Michael Wechsler and Ian D. Pavord as they discuss the future of asthma care. Where will we be in 5 or even 10 years from now? What breakthroughs are on the horizon? Tune in to find out.Medscape (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 11, 2023 Category: Allergy & Immunology Tags: Pulmonary Medicine InDiscussion Source Type: news
Anti-Acid Meds Lower Strength of Systemic Sclerosis Drug Anti-Acid Meds Lower Strength of Systemic Sclerosis Drug
Weakened bioavailability of mycophenolate mofetil could require adjustments in treatment.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 10, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
FDA Approves Intravenous Formulation of Secukinumab FDA Approves Intravenous Formulation of Secukinumab
This new route of administration is expected to become available during the fourth quarter of 2023.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 9, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
Are Women and Men With Rheumatism Treated Equally? Are Women and Men With Rheumatism Treated Equally?
Compared with men, women receive a diagnosis of rheumatic disease much later and are treated more poorly, research suggests.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 9, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
COVID-19 Tied to Autoimmune Disease Risk COVID-19 Tied to Autoimmune Disease Risk
Patients with more severe COVID-19 that required hospitalization in the ICU were more likely to develop vasculitis, alopecia totalis, and several other autoimmune conditions.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
Geographic Distribution of Suspected Alpha-gal Syndrome Cases Geographic Distribution of Suspected Alpha-gal Syndrome Cases
According to this report, the number of cases of alpha-gal syndrome in the United States has increased substantially since 2010, primarily in states with established populations of lone star ticks.Morbidity & Mortality Weekly Report (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2023 Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news
FDA OKs Ninth Humira Biosimilar, With Interchangeability FDA OKs Ninth Humira Biosimilar, With Interchangeability
The drug, adalimumab-afzb (Abrilada), is the second adalimumab biosimilar approved with interchangeability status. It will be available later this month.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 6, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
Change Makers: St éphane Bancel on Revolutionizing Medicine Change Makers: St éphane Bancel on Revolutionizing Medicine
The CEO of Moderna speaks with WebMD CMO John Whyte, MD, MPH, about the potential of mRNA technology and much more.Medscape (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 5, 2023 Category: Allergy & Immunology Tags: Public Health & Prevention Expert Interview Source Type: news
Training More Doctors Should Be Our First Priority: Ethicist Training More Doctors Should Be Our First Priority: Ethicist
Although medical schools are concerned that race should no longer be considered for admission to medical school, our first goal should be to train more doctors, says Art Caplan, PhD.Medscape Business of Medicine (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 5, 2023 Category: Allergy & Immunology Tags: Family Medicine/Primary Care Commentary Source Type: news
Study Finds Higher Prevalence of ACD Among Children With AD Study Finds Higher Prevalence of ACD Among Children With AD
More children with AD should be evaluated for ACD and undergo patch testing, study authors say.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 4, 2023 Category: Allergy & Immunology Tags: Dermatology News Source Type: news
Health Care Provider Knowledge Regarding Alpha-gal Syndrome Health Care Provider Knowledge Regarding Alpha-gal Syndrome
This nationwide CDC survey revealed a concerning gap in clinicians ' knowledge of alpha-gal syndrome, with over 40% unaware of it and another 35% unsure of their ability to diagnose or manage it.Morbidity & Mortality Weekly Report (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 4, 2023 Category: Allergy & Immunology Tags: Public Health & Prevention Journal Article Source Type: news
Tapering Lupus Drugs in Stable Patients: Flare Risks Studied Tapering Lupus Drugs in Stable Patients: Flare Risks Studied
Tapering is best reserved for those in complete remission with stable disease for at least 6 months, although many individual patient characteristics must be taken into account, experts say.MDedge News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - October 3, 2023 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news
